2.99

0.33% -0.010

After Hours: 3.03 0.04 +1.34%

Allogene Therapeutics Inc (ALLO)

Overview News Price History Option Chain Financials Discussions Forecast

Allogene Therapeutics Inc stock is traded at $2.99, with a volume of 2.59M. It is down -0.33% in the last 24 hours and up +10.74% over the past month. Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

Previous Close:

$3.00

Open:

$2.96

24h Volume:

2.59M

Relative Volume:

1.35

Market Cap:

$627.33M

Revenue:

$95,000

Net Income/Loss:

$-327.27M

P/E Ratio:

-1.2204

EPS:

-2.45

Net Cash Flow:

$-239.25M

1W Performance:

+6.79%

1M Performance:

+10.74%

6M Performance:

-2.61%

1Y Performance:

-14.57%

1-Day Range:

$2.88

$3.04

1-Week Range:

$2.54

$3.04

52-Week Range:

$2.01

$5.775

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name

Allogene Therapeutics Inc

Sector

Healthcare (1182)

Industry

Biotechnology (671)

Phone

(650) 457-2700

Address

210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO

Employee

361

Twitter

@AllogeneTx

Next Earnings Date

2024-11-07

Latest SEC Filings

ALLO's Discussions on Twitter

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-05-24	Downgrade	Guggenheim	Buy → Neutral
Jan-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-08-23	Initiated	Citigroup	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Jan-24-23	Upgrade	JP Morgan	Neutral → Overweight
Jan-06-23	Upgrade	Robert W. Baird	Neutral → Outperform
Dec-12-22	Downgrade	BofA Securities	Buy → Underperform
Aug-10-22	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-15-22	Upgrade	Goldman	Neutral → Buy
Jun-03-22	Initiated	Robert W. Baird	Neutral
Feb-28-22	Reiterated	B. Riley Securities	Buy
Oct-20-21	Initiated	Cowen	Outperform
Oct-08-21	Downgrade	Goldman	Buy → Neutral
Oct-08-21	Downgrade	Stifel	Buy → Hold
Sep-23-21	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-21-21	Resumed	Jefferies	Buy
May-20-21	Upgrade	Truist	Hold → Buy
May-14-21	Initiated	B. Riley Securities	Buy
Jan-26-21	Upgrade	Stifel	Hold → Buy
Dec-10-20	Resumed	H.C. Wainwright	Buy
Nov-24-20	Initiated	BofA Securities	Buy
Oct-23-20	Initiated	RBC Capital Mkts	Outperform
Jun-01-20	Downgrade	Raymond James	Outperform → Mkt Perform
May-29-20	Reiterated	H.C. Wainwright	Buy
May-19-20	Upgrade	ROTH Capital	Neutral → Buy
May-15-20	Upgrade	Guggenheim	Neutral → Buy
May-14-20	Reiterated	H.C. Wainwright	Buy
May-14-20	Downgrade	SunTrust	Buy → Hold
Apr-13-20	Initiated	SunTrust	Buy
Mar-13-20	Initiated	H.C. Wainwright	Buy
Mar-05-20	Initiated	Stifel	Hold
Feb-24-20	Initiated	Berenberg	Hold
Dec-18-19	Initiated	JMP Securities	Mkt Outperform
Nov-04-19	Initiated	Canaccord Genuity	Buy
Aug-09-19	Initiated	BTIG Research	Buy
Jun-05-19	Initiated	ROTH Capital	Neutral
May-31-19	Initiated	Guggenheim	Neutral
May-23-19	Initiated	Stifel	Hold
Mar-29-19	Initiated	Piper Jaffray	Overweight

View All

Allogene Therapeutics Inc Stock (ALLO) Latest News

09:11 AM

Allogene Therapeutics to Present New Data Demonstrating the - GlobeNewswire

09:11 AM

09:10 AM

Allogene Therapeutics to Present New Data Demonstrating the Potential of Allo-316 in Heavily Pretreated Adult Patients with Cd70 Positive Advanced Renal Cell Carcinoma At the International Kidney Cancer Symposium and Society for Immunotherapy of Ca - Marketscreener.com

09:10 AM

Nov 04, 2024

Allogene Therapeutics (NASDAQ:ALLO) Trading 6.3% HigherTime to Buy? - MarketBeat

Nov 04, 2024

Palisade Bio (NASDAQ:PALI) and Allogene Therapeutics (NASDAQ:ALLO) Critical Survey - Defense World

Nov 04, 2024

Allogene Therapeutics Announces Participation in November Investor Conferences - StockTitan

Nov 04, 2024

Nov 02, 2024

Allogene Therapeutics’ (ALLO) “Buy” Rating Reiterated at HC Wainwright - Defense World

Nov 02, 2024

Oct 31, 2024

Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance

Oct 31, 2024

Allogene Therapeutics (ALLO) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat

Oct 31, 2024

Allogene shares hold buy rating as FDA grants RMAT to ALLO-316 - Investing.com Australia

Oct 31, 2024

Oct 30, 2024

HC Wainwright Reiterates "Buy" Rating for Allogene Therapeutics (NASDAQ:ALLO) - MarketBeat

Oct 30, 2024

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update - GlobeNewswire

Oct 30, 2024

Oct 29, 2024

FDA grants RMAT status to Allogene's kidney cancer therapy By Investing.com - Investing.com South Africa

Oct 29, 2024

FDA grants RMAT status to Allogene's kidney cancer therapy - Investing.com

Oct 29, 2024

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully - Yahoo Finance

Oct 29, 2024

Allogene Therapeutics Receives FDA Regenerative Medicine - GlobeNewswire

Oct 29, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Oct 29, 2024

Oct 28, 2024

Allogene Therapeutics (NASDAQ:ALLO) Stock Price Up 6.6%Time to Buy? - MarketBeat

Oct 28, 2024

Allogene Therapeutics Inc (NASDAQ: ALLO) Stock Forecast: Could Pass $55 In A Year - Stocks Register

Oct 28, 2024

Oct 24, 2024

Allogene Therapeutics (NASDAQ:ALLO) Shares Down 5.4%Should You Sell? - MarketBeat

Oct 24, 2024

Research Analysts Offer Predictions for ALLO Q3 Earnings - MarketBeat

Oct 24, 2024

Oct 22, 2024

Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.

Oct 22, 2024

Exchange Traded Concepts LLC Acquires 12,328 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World

Oct 22, 2024

Oct 19, 2024

AQR Capital Management LLC Purchases Shares of 27,287 Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World

Oct 19, 2024

Oct 18, 2024

Allogene Therapeutics (ALLO) Stock Surges Amid Biotechnology Sec - GuruFocus.com

Oct 18, 2024

Oct 16, 2024

Wall Street analysts’ outlook for Allogene Therapeutics Inc (ALLO) - SETE News

Oct 16, 2024

Oct 14, 2024